GSKGlaxoSmithKlineNot started yet
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Endometrial Carcinoma · Neoplasms, Endometrial
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 378 (planned)
- Started
- Nov 12, 2026
- Main results expected
- Nov 5, 2030
- Fully finished
- Nov 5, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Serum Trough Concentration (Ctrough) After First Dose of Dostarlimab
Measured over: Up to 42 days
Part 1: Area Under the Concentration-time Curve (AUC) of Dostarlimab
Measured over: Up to 42 days
Part 2: Observed Ctrough of Dostarlimab
Measured over: Up to 168 days
Part 2: Model-predicted (MP) AUC of Dostarlimab
Measured over: Up to 21 days
Part 2: MP AUC of Dostarlimab
Measured over: Up to 168 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07860450 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC